Pond Technologies Holdings Inc. · TSXV:POND
Pond Technologies — Investor Presentation (April 2021)
24 slides from Pond Technologies's investor presentation, April 2021
Slide 1: TSX.V: POND, OTCQB: PNDHF
1 TSX.V: POND, OTCQB: PNDHF January 2021
Slide 2: Advisory
2 ADVISORY This presentation contains forward-looking statements and information (collectively referred to as "forward-looking information") within the meaning of applicable securities laws about Pond's projections, targets and estimates based on certain assumptions disclosed in this advisory and in
Slide 3: Pond: Overview
3 POND: OVERVIEW • Pond Technology has developed a disruptive technology platform that has been proven to grow various species of algae faster and with better quality than any other method • Pond’s technology is protected by 9 US patents as well as 19 international patents in various European and Mi
Slide 4: Pond: How Pond Technology Works
4 POND: HOW POND TECHNOLOGY WORKS Pond transforms CO2 from any source into valuable algae products Driving the future of an algae based bio-economy
Slide 5: Market | Growing Opportunities
5 MARKET | GROWING OPPORTUNITIES The market for algae is a multibillion-dollar industry, and our patented technology can capture all market segments NUTRACEUTICALS FOOD COLOURANTS Target Market: >$10 billion Target Market: >$2 billion CAGR: 10% – 20% CAGR: 4% – 7%, accelerating Price per tonne: $10,
Slide 6: Pond: Controlled Growth Outperforms
6 POND: CONTROLLED GROWTH OUTPERFORMS Pond boosts the productivity of micro-algae beyond the power of nature Current Competitors: Pond‘s Growth Platform: Outdoor methods: • Controls total growth • Algae grows in top few environment including light, inches only- gases and temperature in enclosed phot
Slide 7: Pond: Business Units by Priority
7 POND: BUSINESS UNITS BY PRIORITY Across multiple sectors to fully exploit our platform technology POND BIOTECH (BIO-PHARMA DIAGNOSTICS AND THERAPEUTICS) Pond Biotech grows genetically modified algae that express complex proteins used in diagnostics, therapeutics and medicines. The division was cre
Slide 8: Pond Biotech: Bio-Pharma Division
8 POND BIOTECH :BIO-PHARMA DIVISION The initial business focus is on the development and growth of genetically modified algae strains that can express valuable proteins for use in diagnostic and therapeutic applications. The division was created to become a CMO for bio-tech and pharmaceutical compan
Slide 9: Problem for Pharma – Proteins at scale for Diagnostics and Therapeutics
9 Problem for Pharma – Proteins at scale for Diagnostics and Therapeutics • Current production of complex proteins in Yeast, Bacteria and Mammalian Cell Lines. This can lead to quality issues and high waste. • The current system for cultivating these proteins is expensive compared to Algae. • Diffic
Slide 10: Pond Platform Solution for Bio-Pharma
10 Pond Platform Solution for Bio-Pharma • Controlled growth environment for genetically modified algae that can express proteins for diagnostics and therapeutics. • Consistent quality due to contained growth system. • Proven scalability. • Proper protein folding. • Less expensive.
Slide 11: Pond Naturals
pendtech POND NATURALS 11
Slide 12: Pond Naturals: Fast Tracking Revenues
12 POND NATURALS: FAST TRACKING REVENUES Pond Naturals is a revenue producing division with existing commercial production and extraction of astaxanthin located in Agassiz B.C. FACILITY: ASTAXANTHIN PLANT • Technology improvements underway to deliver expanded capacity to produce and extract over $1,
Slide 13: Pond Naturals: Fast Tracking Revenues
13 POND NATURALS: FAST TRACKING REVENUES Existing commercial production and extraction of astaxanthin located in Agassiz B.C. All-natural extraction process + potential combination with CBD is raising profile of Pond Astaxanthin among major customers Covid -19 is increasing awareness of Astaxanthin
Slide 14: Pond Naturals: Products and Revenue
14 POND NATURALS: PRODUCTS AND REVENUE • Pond Naturals grows and sells Astaxanthin at its BC facility and sells ingredients • Patent pending all-natural extraction process at Pond’s BC facility, yields a premium value astaxanthin, nature’s highest anti-oxidant • Ingredients include: microalgae, anti
Slide 15: Pond Tech
pendtech POND TECH 15
Slide 16: PondTech: Technology Platform
16 PONDTECH: TECHNOLOGY PLATFORM Pond provides optimal growth conditions for algae, producing sustainable protein, nutraceuticals, and more Pond Algae Platform Algae is expected to be the future of plant-based feeds for livestock; it is high in protein, with a complete amino-acid profile, sustainabl
Slide 17: PondTech - Algae for Humans and Animals using Industrial Emissions
17 PondTech - Algae for Humans and Animals using Industrial Emissions • Pond’s proprietary growth system uses Photobioreactors to optimize growth conditions to maximize Algae will be the future of plant-based algae output. feeds for livestock; it’s high in protein, • Protected by an extensive with a
Slide 18: PondTech: Modular Photobioreactor for Export
18 PONDTECH: MODULAR PHOTOBIOREACTOR FOR EXPORT PondTech sale of PBR’s allows companies the ability to inexpensively test the technology and algae strains against their emissions, de-risking new projects globally and shortening Pond’s sales cycle • Fully integrated modular facility for testing input
Slide 19: Pond Tech: License Extensive IP Portfolio
19 POND TECH: LICENSE EXTENSIVE IP PORTFOLIO Pond has a global patent portfolio covering its platform and algae production >9 Patents Pending Active US Patents Algae Platform Protection 9 US patents in process, with over 3x Modulation patents protect 24 International Patents in process more patents
Slide 20: Pond Tech: Licensing Strategy
20 POND TECH: LICENSING STRATEGY Pond has engaged with project developers and funders to advance the agenda Europe: • UK-based Remedi!ate** Licensee $500,000 upfront license fee revenue in 2021 with $2,000,000 minimum annual revenue ongoing North America • US-based BioCarbN and others are developing
Slide 21: Pond: Leadership
21 POND: LEADERSHIP A strong team to realize our vision GRANT SMITH THOMAS MASNEY EMIDIO DI PIETRO PETER HOWARD Chief Executive Officer Chief Financial Officer VP, Engineering VP Project Development Executive with 20+ years experience in Worked with Goldman Sachs & GE in Comprehensive experience in
Slide 22: Pond: Leadership
22 POND: LEADERSHIP Pond has built a track record of scientific excellence that has led us to develop a leading technology platform • Anthony Giovinazzo has been appointed to the POND Board of Directors in September 2020 with the vision of growing the POND BIOTECH unit. • Mr. Giovinazzo was founder,
Slide 23: Cap Table: Feb. 2021
23 CAP TABLE: FEB. 2021 Shares / Warrants Number Common Shares Issued: 42.3 million Reserved for Regenurex Acquisition: 4.6 million Common Shares Issued and Reserved 46.9 million (Insiders control 8.9 Million shares ~19%) Warrants: $0.45 / share Exp. March 2023 10 million Warrants: $0.25 / share Exp
Slide 24: Pond: Contact Information
24 POND: CONTACT INFORMATION Pond Technologies Holdings Inc. Head Office 250 Shields Court, Unit 8 Markham, Ontario L3R 9W7 Tel. +1 (416) 287-3835 g.smith@pondtech.com Please see the Advisory for references and assumptions
Pond Technologies Holdings — Investor Presentation (April 2021) on 6ix